11:51 AM EST, 11/15/2024 (MT Newswires) -- Novartis (NVS) unit Novartis Pharmaceuticals Canada said Friday that negotiations with the pan-Canadian Pharmaceutical Alliance for Pluvicto, a treatment for patients with a certain type of prostate cancer, have closed without an agreement.

"This outcome is a significant setback for people living with [metastatic castration-resistant prostate cancer] whose cancer is progressing despite standard therapies," Novartis Canada said.

Price: 103.19, Change: -0.22, Percent Change: -0.21